Trans-Ethnic Fine-Mapping of Lipid Loci Identifies Population-Specific Signals and Allelic Heterogeneity That Increases the Trait Variance Explained

Ying Wu1, Lindsay L. Waite2, Anne U. Jackson3, Wayne H-H. Shu4,5,6, Steven Buyske7, Devin Absher2, Donna K. Arnett8, Eric Boerwinkle9, Lori L. Bonnycastle10, Cara L. Carty11, Iona Cheng12, Barbara Cochran13, Damien C. Croteau-Chonka1, Logan Dumitrescu13, Charles B. Eaton14, Nora Franceschini15, Xiqing Guo16, Brian E. Henderson17, Lucia A. Hindorff18, Eric Kim16, Leena Kinnunen19, Pirjo Komulainen20, Wen-Jane Lee21, Loic Le Marchand12, Yi Lin11, Jaana Lindström19, Oddieg Lingas-Holmen22, Sabrina L. Mitchell13, Narisu Narisu16, Jennifer G. Robinson23, Fred Schumacher17, Alena Stančáková24, Jouko Sundvall25, Yun-Ju Sung26, Amy J. Swift10, Wen-Chang Wang27, Lynne Wilkens12, Tom Wilsaard28, Alicia M. Young11, Linda S. Adair29, Christie M. Ballantyne30, Petra Büžkova31, Aravinda Chakravarti32, Francis S. Collins10, David Duggan33, Alan B. Ferani24, Low-Tone Ho3,35, Yi-Jen Hung36, Steven C. Hunt37, Kristian Hveem38, Jyh-Ming J. Juang38, Antero Y. Kesäniemi39, Johanna Kuusisto24, Markku Laakso24, Timo A. Lakka20,40, I-Te Lee4,5, Mark F. Leppert41, Tara C. Matise42, Leena Moilanen43,44, Inger Njølstad28, Ulrike Peters11,45, Thomas Quertermous46, Rainer Rauramaa40,47, Jerome I. Rotter16, Jouko Saramies48,49, Jaakko Tuomilehto19,49,50,51, Matti Uusitupa52,53, Tzung-Dau Wang38, Michael Boehnke31, Christopher A. Haiman77, Yi-Der I. Chen161, Charles Kooperberg115, Themistocles L. Assimes46, Dana C. Crawford131, Chao A. Hsiung27, Kari E. North15,54, Karen L. Mohlke15,54,*

1 Department of Genetics, University of North Carolina, Chapel Hill, North Carolina, United States of America, 2 HudsonAlpha Institute for Biotechnology, Huntsville, Alabama, United States of America, 3 Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, Michigan, United States of America, 4 Division of Endocrine and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, 5 School of Medicine, National Yang-Ming University, Taipei, Taiwan, 6 College of Medicine, National Defense Medical Center, Taipei, Taiwan, 7 Department of Statistics and Biostatistics, Rutgers University, Piscataway, New Jersey, United States of America, 8 Department of Epidemiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America, 9 The Human Genetics Center, University of Texas Health Science Center, Houston, Texas, United States of America, 10 Genome Technology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America, 11 Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America, 12 University of Hawaii Cancer Center, Honolulu, Hawaii, United States of America, 13 Department of Molecular Physiology and Biophysics, Center for Human Genetics Research, Vanderbilt University, Nashville, Tennessee, United States of America, 14 Departments of Family Medicine and Epidemiology, Alpert Medical School, Brown University, Providence, Rhode Island, United States of America, 15 Department of Epidemiology, University of North Carolina, Chapel Hill, North Carolina, United States of America, 16 Medical Genetics Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States of America, 17 Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America, 18 Office of Population Genomics, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America, 19 Diabetes Prevention Unit, National Institute for Health and Welfare, Helsinki, Finland, 20 Kuopio Research Institute of Exercise Medicine, Kuopio, Finland, 21 Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan, 22 HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Levanger, Norway, 23 University of Iowa, Iowa City, Iowa, United States of America, 24 Department of Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, 25 National Institute for Health and Welfare, Disease Risk Unit, Helsinki, Finland, 26 Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri, United States of America, 27 Division of Biostatistics and Bioinformatics, Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan, 28 Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, Tromsø, Norway, 29 Department of Nutrition, University of North Carolina, Chapel Hill, North Carolina, United States of America, 30 Baylor College of Medicine, Houston, Texas, United States of America, 31 Department of Biostatistics, University of Washington, Seattle, Washington, United States of America, 32 Center for Complex Disease Genomics, McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, 33 Translational Genomics Research Institute, Phoenix, Arizona, United States of America, 34 Office of Population Studies Foundation, University of San Carlos, Cebu, Philippines, 35 Department of Internal Medicine and Department of Medical Research and Education, Taipei Veterans General Hospital, Taipei, Taiwan, 36 Division of Endocrinology and Metabolism, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, 37 Department of Internal Medicine, University of Utah, Salt Lake City, Utah, United States of America, 38 Cardiovascular Center and Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan, 39 Institute of Clinical Medicine, Department of Medicine, University of Oslo and Clinical Research Center, Oslo University Hospital, Oslo, Finland, 40 Institute of Biomedicine/Physiology, University of Eastern Finland, Kuopio Campus, Kuopio, Finland, 41 Department of Human Genetics, University of Utah School of Medicine, Salt Lake City, Utah, United States of America, 42 Department of Genetics, Rutgers University, Piscataway, New Jersey, United States of America, 43 Department of Medicine, Kuopio University Hospital, Kuopio, Finland, 44 Pirkanmaa Hospital District, Tampere, Finland, 45 School of Public Health, University of Washington, Seattle, Washington, United States of America, 46 Department of Medicine, Stanford University School of Medicine, Stanford, California, United States of America, 47 Department of Clinical Physiology and Nuclear Medicine, Kuopio University Hospital, Kuopio, Finland, 48 South Karelia Central Hospital, Lappeenranta, Finland, 49 South Ostrobothnia Central Hospital, Seinäjoki, Finland, 50 Red RECAU Grupo RD06/011/0015, Hospital Universitario La Paz, Madrid, Spain, 51 Centre for Vascular Prevention, Danube-University Krems, Krems, Austria, 52 Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland, 53 Research Unit, Kuopio University Hospital, Kuopio, Finland, 54 Carolina Center for Genome Sciences, University of North Carolina, Chapel Hill, North Carolina, United States of America

PLOS Genetics | www.plosgenetics.org 1 March 2013 | Volume 9 | Issue 3 | e1003379
Abstract

Genome-wide association studies (GWAS) have identified ~100 loci associated with blood lipid levels, but much of the trait heritability remains unexplained, and at most loci the identities of the trait-influencing variants remain unknown. We conducted a trans-ethnic fine-mapping study at 18, 22, and 18 GWAS loci on the Metabochip for their association with triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), respectively, in individuals of African American (n = 6,832), East Asian (n = 9,449), and European (n = 10,829) ancestry. We aimed to identify the variants with strongest association at each locus, identify additional and population-specific signals, refine association signals, and assess the relative significance of previously described functional variants. Among the 58 loci, 33 exhibited evidence of association at $P < 1\times10^{-4}$ in at least one ancestry group. Sequential conditional analyses revealed that ten, nine, and four loci in African Americans, Europeans, and East Asians, respectively, exhibited two or more signals. At these loci, accounting for all signals led to a 1.3- to 1.8-fold increase in the explained phenotypic variance compared to the strongest signals. Distinct signals across ancestry groups were identified at PCSK9 and APOA5. Trans-ethnic analyses narrowed the signals to smaller sets of variants at GCKR, PPBP138, ABO, LCAT, and ABCA1. Of 27 variants reported previously to have functional effects, 74% exhibited the strongest association at the respective signal. In conclusion, trans-ethnic high-density genotyping and analysis confirm the presence of allelic heterogeneity, allow the identification of population-specific variants, and limit the number of candidate SNPs for functional studies.

Citation: Wu Y, Waite LL, Jackson AU, Sheu WH-H, Buyse S, et al. (2013) Trans-Ethnic Fine-Mapping of Lipid Loci Identifies Population-Specific Signals and Allelic Heterogeneity That Increases the Trait Variance Explained. PLoS Genet 9(3): e1003379. doi:10.1371/journal.pgen.1003379

Editor: Greg Gibson, Georgia Institute of Technology, United States of America

Received August 1, 2012; Accepted January 19, 2013; Published March 21, 2013

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: The data and materials included in this report result from a collaboration among the following studies. PAGE: The Population Architecture Using Genomics and Epidemiology (PAGE) program is funded by the National Human Genome Research Institute (NHGRI), supported by U01HG004803 (CALiCo), U01HG004798 (EAGLE), U01HG004802 (MEX), U01HG004790 (WHI), and U01HG004801 (Coordinating Center), and their respective NHGRI ARRA supplements. The contents of this paper are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. Funding support for the Genetic Epidemiology of Causal Variants Across the Life Course (CALiCo) program was provided through the NHGRI PAGE program (U01HG004803 and its NHGRI ARRA supplement). The Atherosclerosis Risk in Communities (ARIC) Study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts N01-HC-55015, N01-HC-55016, N01-HC-55018, N01-HC-55019, N01-HC-55020, N01-HC-55021, and N01-HC-55022. The Multiethnic Cohort study (MEC) characterization of epidemiological architecture is funded through the NHGRI PAGE program (U01HG004802 and its NHGRI ARRA supplement). The MEC study is funded through the National Cancer Institute (R03CA154821, R01 CA63, P01CA33619, U01CA136792, and U01CA98758). Funding support for the “Epidemiology of putative genetic variants: The Women’s Health Initiative” study is provided through the NHGRI PAGE program (U01HG004790 and its NHGRI ARRA supplement). The WHI network is funded by the National Heart, Lung, and Blood Institute; NIH; and U.S. Department of Health and Human Services through contracts N01-WH22110, 24152, 32100-2, 32105-6, 32108-9, 32111-13, 32115, 32118-32119, 32122, 42107-26, 42129-32, and 44221. Assistance with phenotype annotation, SNP selection and annotation, data cleaning, data management, integration and dissemination, and general study coordination was provided by the PAGE Coordinating Center (U01HG004801-01 and its NHGRI ARRA supplement). The National Institutes of Mental Health also contributes to the support for the Coordinating Center. HyperGEN: The hypertension network is funded by cooperative agreements (U01) with NHLBI: HL54471, HL54472, HL54473, HL54479, HL54496, HL54497, HL54509, HL54515, and 2 R01 HL55673-12. CLHNS: The Cebu Longitudinal Health and Nutrition Survey (CLHNS) was supported by National Institutes of Health grants DK078150, TW05596, and HL085144 and pilot funds from RR02649, ES10126, and DK65330. TAICHI: The TAICHI Metabochip study was supported by NHLBI grant HL087647. Financial support for HALST was through grants from the National Health Research Institutes (PH-100-SP-01). The SAPPHIRE was supported by grants from the National Health Research Institutes (BS-094-PP-01 and PH-100-PP-03). The TCAGEN was partially supported by grants N1T01HL67207, N1T01HL67208, N1T01HL67209, N1T01HL67210, N1T01HL67211, N1T01HL67212, N1T01HL67213, N1T01HL67214, N1T01HL67215, N1T01HL67216, N1T01HL67217, N1T01HL67218, N1T01HL67219, N1T01HL67220, and N1T01HL67221. The MEC study is supported by National Institutes of Health grants DK078150, TW05596, and HL085144 and pilot funds from RR02649, ES10126, and DK65330. TROMSØ: This study was supported by University of Tromsø, Norwegian Research Council (project number 185764). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: mohlike@med.unc.edu

These authors were joint senior authors on this work.

Introduction

Genome-wide association studies (GWAS) have identified many common genetic variants associated with human diseases and complex traits [www.genome.gov/gwastudies], including ~100 loci associated with triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), or total cholesterol [1-5]. A majority of the lead SNPs at these loci

Trans-ethnic Fine-Mapping of Lipid Loci
have shown small effect sizes, leaving much of the trait heritability unexplained. Some of this missing heritability may be due to the incomplete coverage of functional common or rare variants and the poor representation of appropriate proxies on commercial genotyping arrays [6,7]. Other missing heritability may result from a failure to detect the full spectrum of causative variants present at GWAS-identified loci.

Fine-mapping of GWAS signals should increase the power to detect variants that influence trait variability. Genotyping of additional variants at GWAS loci can identify SNPs with stronger evidence of association than the reported GWAS index SNPs and may help detect or further localize the underlying causal variants [7,8]. The Metabochip is a high-density custom genotyping array designed to replicate and fine-map known GWAS signals for metabolic and atherosclerotic/cardiovascular endpoints, and more extensively, to identify all signals around the index SNPs [9,10]. The fine-mapping SNPs spanned a wide range of allele frequencies including rare (minor allele frequency (MAF)<0.005) and less common (0.005≤MAF<0.05) SNPs selected from the catalogs of the International HapMap Project and the August 2009 release of the 1000 Genomes Project. SNPs annotated as nonsynonymous, essential splice site or stop codon were included regardless of MAF, design score, or the presence of nearby SNPs [10]. The Metabochip contains densely spaced SNPs at 18, 22, and 18 loci previously reported for TG, HDL-C, and LDL-C, respectively. Allelic heterogeneity, in which different variants at the same gene/locus affect the same phenotype, is a frequent characteristic of both single-gene and complex disorders. Recently GWAS have identified more than one independent signal at loci associated with coronary artery disease [11] and type 2 diabetes [12,13]. Among a set of 30 lipid loci reported through GWAS, secondary SNPs that exhibited weak to moderate LD with the corresponding index SNPs and displayed little change of association in conditional analyses were detected at seven loci including CETP, LIPC, APOA5, APOE, LDLR, ABCG8, and LPL [4]. More than one association signal was also detected at 26 of 95 lipid loci reported by the Global Lipids Genetics Consortium [5]. However, allelic heterogeneity has not been comprehensively evaluated for common traits including lipid traits across ethnically diverse populations, especially in non-European populations such as African Americans and East Asians.

Due to divergent evolutionary and migratory histories, patterns of linkage disequilibrium (LD) vary across ancestry groups [14]. Greater haplotype diversity in some ancestry groups, especially in African ancestry populations, may facilitate the localization of functional variants that show association signals delimited in part due to weaker LD with neighboring SNPs [14,15]. A recent multi-ethnic analysis of lipid associated loci demonstrated that genetic determinants at many lipid loci differed between European Americans and African Americans [16]. For example, in African Americans from the PAGE consortium [9,17], a reported regulatory variant rs12740374 at CELSR2/PSRC1/SORT1 locus [18] was more strongly associated with LDL-C compared to many nearby variants demonstrating similar strength of association in European ancestry individuals [5]. High-density genotyping enables trans-ethnic fine-mapping studies to narrow the set of plausible candidate functional variants at GWAS loci without introducing uncertainty through imputation [19]. In this study, we analyzed high-density genotyped SNPs on the Metabochip for their associations with TG, HDL-C, and LDL-C in 6,832 African Americans, 9,449 East Asians, and 10,829 Europeans at 58 known lipid loci. We sought to (i) identify the variants with the strongest evidence of association at each locus in populations with different ancestries and in the combined trans-ethnic samples; (ii) investigate allelic heterogeneity and population-specific signals at the established lipid loci; (iii) explore whether high-density genotyping in diverse ethnic populations would narrow the sets of plausible candidate functional variants for further study; and (iv) assess whether the variants reported to have functional effects on gene expression or protein function during the past 30 years of biological study exhibited the strongest evidence of association at the corresponding GWAS signals.

**Results**

Loci with evidence of association in diverse populations and in the combined trans-ethnic samples

Descriptions of the collection, phenotyping, and genotyping of study samples for each study site are provided in Table S1. Given that all 58 loci have a priori genome-wide significant evidence of association with one or more of these three lipid traits, we used a $P$ value threshold of $1 \times 10^{-4}$ as an approximate correction for the mean of 451 SNPs tested at each locus in African Americans (Table S2). An average of 273 SNPs per locus was tested in East Asians and an average of 291 in Europeans, but we applied the same, more conservative, P value threshold of $1 \times 10^{-4}$ to these two groups as well.

A total of 33 loci (nine for TG, 14 for HDL-C, and 10 for LDL-C) exhibited evidence of association at $P<1 \times 10^{-4}$ in at least one of the three ancestry groups, including 22 loci in African Americans, 17 in East Asians, and 31 in Europeans (Table S3A–S3C). The variants that reached this threshold of significance were common (MAF≥0.05), except at three loci (PCSK9 and ABO for LDL-C, and APOA5 for HDL-C) in African Americans and two loci (PCSK9 and TOP1, both for LDL-C) in European ancestry individuals. When individuals of diverse ancestry groups were combined, 11, 15, and 12 loci showed evidence of significant association with TG, HDL-C, and LDL-C, respectively (Table S4A–S4C). Among these 38 loci, six loci had not reached the $P$ value threshold of $10^{-4}$ within any individual ancestry group, including CETP and NAT for TG, GALNT2 and MIMAB for HDL-C, and TRIB1 and TIMD4 for LDL-C. One locus, COBLL1, was
significantly associated with HDL-C in Europeans alone ($P=0.5 \times 10^{-5}$), but displayed less evidence of association in the combined trans-ethnic samples ($P=1.6 \times 10^{-4}$).

**Loci with evidence of multiple signals at a locus, and often population-specific signals**

To assess the presence of two or more signals at each locus that exhibited evidence of association in at least one ancestry group, we performed sequential conditional analyses by adding the most strongly associated SNP to the regression model as a covariate and testing the association with each of the remaining regional SNPs independently. A set of sequential conditional analyses were followed by inclusion of the strongest SNP in each conditional model until the most strongly associated SNP showed a conditional $P$ value $>10^{-3}$ and was not annotated as a nonsense or nonsynonymous substitution. We also investigated whether association signals were population-specific, which we defined as association signals with variants that are not variable in the samples from the other two ancestry groups in this study or in the 1000 Genomes Project populations that represent those groups among total European ancestry (EUR), total East Asian ancestry (ASN), or total west African ancestry (AFR).

In African Americans, sequential conditional analyses revealed that 10 of the 22 loci with evidence of association exhibited two or more signals at $P<10^{-4}$ (Table 1). Two loci (PCS$9\alpha$ and the TOMM$40$-APOE-APOC$4$ cluster; both for LDL-C) each had seven signals, four loci (APOB for LDL-C, LDLR for LDL-C, LCAT for HDL-C, and CETP for HDL-C) had three signals, and another four loci (APOB, APOC$1$, APOA$5$, and LPL; all for TG) had two signals. Among the 10 loci with two or more signals, all these signals led to an average 1.8-fold increase in the amount of phenotypic variance ($R^2$) compared to that explained by the strongest signals alone (See Method) in African Americans. Among these 34 signals, 15 were represented by less common (0.005 $\leq$ MAF $< 0.05$, $n=11$) or rare (MAF $< 0.005$, $n=4$) variants. In addition, 15 signals at eight loci were African American-specific. If we only include SNPs that meet a locus-specific $P$-value threshold based on the number of genotyped SNPs (Table S2), LPL for TG and APOB for both TG and LDL-C each had one signal, and the seven loci with multiple signals still showed an average of 1.8-fold increase in the explained phenotypic variance.

The seven signals at PCS$9\alpha$ in African Americans included six nonsense or nonsynonymous variants previously shown to associate with LDL-C levels and to affect PCS$9\alpha$ expression or function [20–22], along with an unreported intrinsic variant (Table 1). The strongest signals were a nonsense variant rs28362286 (C679X, Figure 1A) and a nonsynonymous variant rs28362263 (A443T, Figure 1B), which showed no reduction of association evidence when conditioned on C679X. Conditional analysis on both C679X and A443T yielded a third signal at $P=1.6 \times 10^{-4}$ (Table 1), and further conditional analyses successively implicated rs67608943 (Y142X, Figure 1D), rs26466409 (A253F, Figure 1E), and an intrinsic variant rs11800245 (Figure 1F). The seventh signal, which did not reach the $P=10^{-4}$ threshold, was represented by the nonsynonymous variant rs11591147 (R46L, Figure 1G) that exhibited the strongest and directionally consistent evidence of association with LDL-C in Europeans ($P_{	ext{initial}}=2.8 \times 10^{-40}$, Table 2). The seven signals were weakly correlated with each other in African American individuals, and all pairwise LD $r^2$ values were less than 0.02. Among the seven PCS$9\alpha$ signals, the top five were African American-specific, and six were either less common or rare in African Americans. The lead SNP C679X accounted for 1.3% of the explained LDL-C phenotypic variance and the seven signals together explained 3.6% of the phenotypic variance in African Americans. PCS$9\alpha$ exhibited two signals in Europeans (R64L and rs2495477, Table 2), but no SNP reached $P_{	ext{initial}}<10^{-4}$ in East Asians.

At the TOMM$40$-APOE-APOC$4$ cluster, the seven signals in African Americans explained 6.6% of the LDL-C phenotypic variance compared to 4.1% explained by the strongest signal R176C, which had reported functional effects [23] (Table 1, Figure S1). These seven signals were not entirely independent of one another. The fourth signal, rs157588, showed association with LDL-C ($P=2.0 \times 10^{-7}$) only after conditioning on the top three signals, but not in the original unconditioned association analysis ($P=0.72$). The trait-decreasing allele (G allele: freq = 0.176) of rs157588 was present on haplotypes containing the trait-increasing allele of the third signal rs1038026 (A allele: freq = 0.351), thus the association of the fourth signal increased in significance after accounting for linkage disequilibrium ($r^2/D=0.35/0.92$) with the third signal at the same locus. Haplotype analysis revealed that compared to the reference A-A (increasing-increasing) haplotype, the G-G (decreasing-decreasing) haplotype only displayed modest association with LDL-C ($P=7.5 \times 10^{-5}$), but the A-G (rs1038026 increasing-rs157588 decreasing) haplotype showed significant association with decreased level of LDL-C ($P=1.5 \times 10^{-10}$) (Table S5). In Europeans (Table 2) and East Asians (Table 3), three and two signals were identified at TOMM$40$-APOE-APOC$4$, respectively. The known functional variant R176C exhibited the strongest evidence of association across the three ancestry groups, with effect sizes of $-0.536$, $-0.505$, and $-0.411$ mmol/L in individuals of African American, European, and East Asian ancestry, respectively (Table 1). However, another APOE variant rs429358 (C130R), that together with R176C defines the three major isoforms of APOE (e2, e3, and e4) [7,24], was not successfully genotyped, therefore the LDL-C association with either C130R or the APOE haplotype was unavailable in this study.

In Europeans, 21 signals at nine of the 31 loci exhibited multiple signals for at least one of the three lipid traits at $P<10^{-4}$ (Table 2). Three loci (APOA5 for TG, TOMM$40$-APOE-APOC$4$ cluster for LDL-C, and CETP for HDL-C) each had three signals while another six loci (PCS$9\alpha$ for LDL-C, GCKR for TG, LIPC for HDL-C, APOB for LDL-C, and LPL for both TG and HDL-C) each had two signals. At the nine loci that had two or more signals, all association signals resulted in an average of 1.3-fold increase in the explained phenotypic variance compared to the strongest signals alone across loci. At PCS$9\alpha$, rs11591147 (R46L) exhibited the strongest evidence of association in Europeans. As reported above, R46L also represented the seventh signal in African Americans. R46L accounted for 1.2% of the total variation in LDL-C levels in Europeans compared the 0.16% in African Americans. This SNP was not variable in the 1000 Genomes Project ASN samples (East Asian ancestry) and the >9,000 East Asian individuals in this study.

In East Asians, we observed three signals at the TG locus APOA5, and two signals at three loci including TOMM$40$-APOE-APOC$4$ cluster for LDL-C, CETP for HDL-C, and ABO for LDL-C (Table 3). At the four loci that exhibited multiple signals, all the association signals increased the explained phenotypic variance by an average of 1.3-fold compared to the strongest signal across loci. The second signal at APOA5 was the nonsynonymous variant G185C previously reported to affect the protein function [23]. Although G185C was not unique to East Asians, the frequency was very low in African Americans (MAF = 0.002, $P=0.028$) and Europeans (MAF = 0.0003, $P=0.23$), and the low allele frequency meant that this study had less than 5% statistical power to detect the association in these groups.
Table 1. Lipid loci with multiple and population-specific signals in African Americans.

| SNP                | Annotation | Effect/non-effect allele | African American (n = 6,832) | Variance explained by the strongest signal | Variance explained by all signals | East Asian (n = 9,449) | European (n = 10,829) |
|--------------------|------------|--------------------------|-----------------------------|------------------------------------------|---------------------------------|------------------------|-----------------------|
|                    |            |                          | EAF LD (\(\chi^2/D\)) | \(P_{\text{initial}}\) | \(P_{\text{conditional}}\) | EAF | \(P_{\text{b}}\) | EAF | \(P_{\text{b}}\) | EAF | \(P_{\text{b}}\) |
| PCSK9 for LDL-C     |            |                          |                            |                              |                                |                        |                        |                        |                        |                        |                        |
| rs28362286         | PCSK9-C679K| A/C                      | 0.009                       | ---                         | -0.956                         | 4.8E-17                | ---                    | 1.3%                  | 3.6%                  | 0                   | ---                    |
| rs28362263         | PCSK9-A443T| A/G                      | 0.097                       | 0.00/1.00                  | -0.206                         | 3.1E-09                | -0.218                 | 2.7E-10               | 0                     | ---                    | ---                    |
| rs38362261         | PCSK9-N425S| A/G                      | 0.985                       | 0.00/1.00                  | 0.361                          | 2.1E-05                | 0.396                  | 3.2E-06               | 0                     | ---                    | ---                    |
| rs67608943         | PCSK9-Y142X| C/G                      | 0.996                       | 0.00/0.00                  | 0.925                          | 1.0E-07                | 0.798                  | 4.2E-06               | 0                     | ---                    | ---                    |
| rs72646508         | PCSK9-L253F| T/C                      | 0.003                       | 0.00/1.00                  | -0.720                         | 9.2E-05                | -0.773                 | 2.9E-05               | 0                     | ---                    | ---                    |
| rs11800243         | PCSK9-intron| A/G                      | 0.044                       | 0.00/1.00                  | -0.152                         | 2.4E-03                | -0.198                 | 7.7E-05               | 0.030                 | -0.070                 | 0.091                 |
| rs11591147         | PCSK9-R46L | T/G                      | 0.003                       | 0.00/1.00                  | -0.595                         | 2.3E-03                | -0.678                 | 5.3E-04               | 0                     | ---                    | ---                    |
| TOMM40-APOE-APOC4 for LDL-C | | | | | | | | | | | |
| rs7412             | APOE-R176C | T/C                      | 0.110                       | ---                         | -0.536                         | 6.7E-75                | ---                    | 4.1%                  | 6.6%                  | 0.086                | -0.411                 |
| rs115299243        | APOE-intron| A/G                      | 0.980                       | 0.00/0.99                  | 0.391                          | 3.4E-09                | 0.436                  | 1.6E-11               | 0                     | ---                    | ---                    |
| rs1038026          | TOMM40-intron| A/G                      | 0.351                       | 0.03/0.70                  | 0.183                          | 7.5E-21                | 0.102                  | 2.6E-07               | 0.664                 | 0.118                 | 3.0E-16               |
| rs157588           | TOMM40-intron| T/C                      | 0.824                       | 0.01/0.43                  | -0.009                         | 0.72                   | 0.153                  | 2.0E-07               | 0.339                 | -0.119                 | 1.1E-16               |
| rs769449           | APOE-intron| A/G                      | 0.024                       | 0.00/0.86                  | 0.302                          | 1.1E-06                | 0.295                  | 4.1E-06               | 0.086                 | 0.173                 | 2.8E-12               |
| rs73939904         | APOC4-upstream| A/C                      | 0.940                       | 0.00/0.16                  | 0.143                          | 2.5E-04                | 0.158                  | 3.8E-05               | 0.986                 | 0.135                 | 0.76                  |
| rs8106922          | TOMM40-intron| T/G                      | 0.756                       | 0.04/0.97                  | -0.110                         | 4.1E-07                | -0.097                 | 9.9E-05               | 0.784                 | -0.027                 | 0.10                 |
| LDLR for LDL-C     |            |                          |                            |                              |                                |                        |                        |                        |                        |                        |                        |
| rs73015011         | ---        | T/C                      | 0.820                       | 0.194                      | 5.7E-16                         | ---                    | 1.0%                  | 1.8%                  | 0.987                | 0.140                 | 0.020                 |
| rs114197570        | LDLR-upstream | T/C                      | 0.010                       | 0.05/1.00                  | -0.689                         | 3.0E-13                | -0.549                 | 1.2E-08               | 0                     | ---                    | ---                    |
| rs113190300        | LDLR-upstream | T/C                      | 0.048                       | 0.22/1.00                  | 0.046                          | 0.29                   | 0.241                  | 1.4E-06               | 0                     | ---                    | ---                    |
| LCAT for HDL-C     |            |                          |                            |                              |                                |                        |                        |                        |                        |                        |                        |
| rs255054           | DEPE3-upstream | A/G                      | 0.789                       | ---                         | -0.044                         | 3.2E-07                | ---                    | 0.3%                  | 0.5%                  | 0.904                | -0.028                 |
| rs114763908        | NFATC3-intron| A/G                      | 0.016                       | 0.00/1.00                  | 0.109                          | 1.1E-04                | 0.118                  | 2.5E-05               | 0                     | ---                    | ---                    |
| rs2230093          | NFATC3-L100S | T/C                      | 0.990                       | 0.00/1.00                  | 0.129                          | 2.5E-04                | 0.120                  | 6.3E-04               | 0                     | ---                    | ---                    |
| APOB for LDL-C     |            |                          |                            |                              |                                |                        |                        |                        |                        |                        |                        |
| rs586938           | ---        | T/C                      | 0.426                       | ---                         | 0.109                          | 1.1E-08                | ---                    | 0.6%                  | 1.0%                  | 0.966                | 0.000                 |
| rs73920524         | ---        | A/G                      | 0.947                       | 0.04/1.00                  | 0.205                          | 9.4E-07                | 0.167                  | 8.8E-05               | 0.999                 | 0.549                 | 0.093                 |
| rs72653060         | APOB-F299V | A/C                      | 0.998                       | 0.00/1.00                  | -1.128                         | 2.6E-04                | -1.151                 | 1.8E-04               | 0                     | ---                    | ---                    |
| CETP for HDL-C     |            |                          |                            |                              |                                |                        |                        |                        |                        |                        |                        |
| rs247617           | CETP-upstream | T/C                      | 0.259                       | ---                         | 0.110                          | 1.1E-42                | ---                    | 2.6%                  | 4.8%                  | 0.166                | 0.071                 |
| rs5883             | CETP-F287F  | T/C                      | 0.101                       | 0.02/0.69                  | 0.088                          | 1.3E-13                | 0.109                  | 1.8E-20               | 0.010                 | 0.017                 | 0.70                  |
| rs17231520         | CETP-SUTR   | A/G                      | 0.069                       | 0.21/0.99                  | 0.175                          | 2.2E-37                | 0.113                  | 1.1E-13               | 0                     | ---                    | ---                    |
Table 1. Cont.

| SNP       | Annotation         | Effect/non-effect allele | African American (n = 6,832) | Variance explained by the strongest signal\(d\) | East Asian (n = 9,449) | European (n = 10,829) |
|-----------|--------------------|--------------------------|-----------------------------|-----------------------------------------------|------------------------|------------------------|
|           |                    |                          |                             | EAF                                           | \(\beta\)               | \(P\)                   | EAF          | \(\beta\)               | \(P\)                   | EAF          | \(\beta\)               | \(P\)                   |
| APOC1-APOE for TG |                   |                          |                             | EAF                                           | \(\beta\)               | \(P\)                   | EAF          | \(\beta\)               | \(P\)                   | EAF          | \(\beta\)               | \(P\)                   |
| rs12721054 | APOC1-3'UTR        | A/G                      | 0.881                       | 0.113                                         | 3.6E-19                 | ---                    | 1.0%        | 0                         | ---                    | 1.6%        | 0                         | ---                    |
| rs769455   | APOE-163C          | T/C                      | 0.020                       | 0.00/0.73                                     | 3.4E-10                 | 0.174                  | 2.6E-09     | 0                         | ---                    | 0           | 0                         | ---                    |
| APOB for TG |                   |                          |                             | EAF                                           | \(\beta\)               | \(P\)                   | EAF          | \(\beta\)               | \(P\)                   | EAF          | \(\beta\)               | \(P\)                   |
| rs676210   | APOB-P2739L        | A/G                      | 0.157                       | ---                                           | -0.052                  | 4.0E-06                | ---          | 0.3%                     | 0.002                  | 0.79        | 0.260                    | -0.047                 | 2.1E-10     |
| rs6752026  | APOB-P1455         | A/G                      | 0.121                       | 0.02/0.98                                     | -0.033                  | 8.8E-03                | -0.043       | 8.9E-04                 | 0.077                  | 7.3E-05     | 0.019                    | 0.069                  | 4.3E-03     |
| APOAS for TG |                   |                          |                             | EAF                                           | \(\beta\)               | \(P\)                   | EAF          | \(\beta\)               | \(P\)                   | EAF          | \(\beta\)               | \(P\)                   |
| rs3135506  | APOAS-S19W         | C/G                      | 0.058                       | ---                                           | 0.136                   | 8.4E-15                | ---          | 0.9%                     | 0.136                  | 0.17        | 0.058                    | 0.121                  | 3.3E-18     |
| rs79624460 | BUD13-intron       | T/C                      | 0.083                       | 0.00/0.88                                     | -0.102                  | 4.8E-12                | -0.095       | 1.4E-10                 | 0.077                  | 7.3E-05     | 0.019                    | 0.069                  | 4.3E-03     |
| LPL for TG |                   |                          |                             | EAF                                           | \(\beta\)               | \(P\)                   | EAF          | \(\beta\)               | \(P\)                   | EAF          | \(\beta\)               | \(P\)                   |
| rs75551077 | LPL-3'UTR          | A/G                      | 0.049                       | 0.01/1.00                                     | 0.086                   | 7.7E-06                | 0.077        | 7.3E-05                 | 0                     | ---         | 0.019                    | 0.069                  | 4.3E-03     |

\(a\) LD \((r^2/D)\) with SNP showing the strongest evidence of association at each locus.

\(b\) \(\beta\) effect size from an additive model and corresponding to the effect allele, in the unit of mmol/L for HDL-C, LDL-C and natural log transformed TG.

\(c\) \(P\) values of initial association in East Asians and Europeans.

\(d\) Variance explained was estimated based on PAGE samples \((n = 5,593)\).

\(e\) \(P\) values of initial association in East Asians and Europeans.

\(f\) Conditional analyses at LDL-C locus PCSK9 were restricted to 5,593 PAGE samples because SNPs rs67608943 (Y142X), rs72646508 (L253F) and rs11591147 (R46L) were not polymorphic in HyperGEN samples.

doi:10.1371/journal.pgen.1003379.t001
Figure 1. LDL-C locus PCSK9 exhibited seven signals in African Americans. Initial association in the main analysis (A). Residual association in sequential conditional analysis by sequentially adding the lead SNPs into the regression model (B–G). Each SNP was colored according to its LD ($r^2$) in the PAGE consortium, with the strongest SNP colored in purple and symbols designating genomic annotation defined in the ‘annotation key’. Genomic coordinates refer to build 36 (hg18).

doi:10.1371/journal.pgen.1003379.g001

At APOA5, which exhibited multiple signals in all three populations (Table 1, Table 2, Table 3), the strongest TG-associated SNPs differed and were not in high LD ($r^2<0.8$) with each other in any of the ancestry groups. In African Americans, the two signals S19W (MAF = 0.058, $P=8.4 \times 10^{-15}$) and rs7624460 (MAF = 0.083, $P=4.8 \times 10^{-12}$), showed no evidence of significant association in East Asians (Table 1), likely due to the low allele frequency and the limited power (~10%) to detect the association. The three signals at APOA5 in East Asians were only modestly associated with TG in African Americans (all $P>0.05$, Table 3). The SNP LD $r^2$ values between the African American and East Asian signals were less than 0.02 in both populations, suggesting that they represent distinct APOA5 signals in the two ancestry groups. In addition, the APOA5 signal rs3741298 ($P=9.7 \times 10^{-14}$, MAF = 0.222) in Europeans exhibited evidence of association with TG in African Americans ($P=9.8 \times 10^{-3}$, MAF = 0.327) and East Asians ($P=1.2 \times 10^{-20}$, MAF = 0.357), but the significance levels of the association with rs3741298 were substantially attenuated by conditioning on the strongest signals S19W in African Americans ($P=0.10$) and rs651821 in East Asians ($P=0.88$). In Europeans, the associations with rs3741298 were partially removed when conditioning on S19W and rs651821 ($P_{\text{conditional}}=1.7 \times 10^{-28}$ and $3.1 \times 10^{-17}$, respectively). The European signal rs3741298 was moderately correlated with the African American signal S19W (LD $r^2=0.21$ and 0.10 in the 1000 Genomes Project EUR samples (European ancestry) and in PAGE African American samples, respectively), and with the East Asian signal rs651821 (LD $r^2=0.31$ and 0.28 in 1000 Genomes Project EUR and ASN samples, respectively). Notably, the effect sizes of the two reported functional variants S19W [26] and G185C [25] at APOA5 were similar across the three groups (S19W, African American: 0.136; East Asian: 0.136; European: 0.121 and G185C, African American: 0.204; East Asian: 0.201; European: 0.269 mmol/L in log, scale) despite the limited power to detect significant evidence of association at low allele frequencies. These findings support the hypothesis that causative variants may have a similar genetic impact on trait variation across populations if not influenced by hidden gene-gene or gene-environment interactions [27]. We also observed that the second European signal rs75919952 exhibited nominal evidence of association ($P_{\text{initial}}=0.018$, MAF=0.041), but was not associated with TG in the other two groups (Table 2). The lack of association may be due to insufficient power (15% and 5% in African Americans and East Asians, respectively, assuming $\alpha=0.05$) corresponding to the lower allele frequency (MAF = 0.012) in African Americans, the smaller sample sizes in both populations, or underlying interactions.

Trans-ethnic high-density genotyping narrowed the region of association signals

We next examined whether trans-ethnic meta-analysis or comparison across ancestries would refine the association signals by narrowing the genomic regions where functional variants might be expected to reside. The trans-ethnic analysis allowed the refinement of association signals at loci of GCKR, PPP1R3B, ABO, LCAT, and ABCA1 (Table 4, Table S3A–S3C). The signal at GCKR was localized to the reported functional variant P446L [28] due to the limited LD in African Americans (Figure S2A–S2D). Notably, there were seven and six variants in high LD ($r^2\geq0.8$) with P446L in the 1000 Genomes Project EUR and ASN samples, but no SNP with LD $r^2>0.8$ in African American individuals. At the signal ~200 kb from the PPP1R3B gene for which no functional regulatory variant(s) have been reported, the association signal was narrowed from 4 SNPs spanning 36 kb ($P<10^{-4}$) in Europeans to two highly correlated SNPs located 1 kb apart in African Americans (rs6601299, $P=8.0 \times 10^{-3}$ and rs481132, $P=2.9 \times 10^{-7}$; LD $r^2>0.94$) (Figure 2). The lead SNP rs6601299 was in high LD with 11 variants in the 1000 Genomes Project EUR samples but only highly correlated with two and one variant in the 1000 Genomes Project AFR samples (West African ancestry) and PAGE African American individuals, respectively. At the ABO locus, trans-ethnic meta-analysis revealed six SNPs exhibiting stronger evidence of association ($P<1.1 \times 10^{-11}$) with LDL-C compared to other variants in the same region ($P>2.3 \times 10^{-7}$) (Figure S3A–S3D). At the locus LCAT for HDL-C, the association signals spanned ~800 kb, ~360 kb, and ~360 kb in Europeans, East Asians, and African Americans, with a ~50 kb overlapping region. Trans-ethnic meta-analysis of all samples localized the signal to four variants spanning this 50 kb region (Figure S4A–S4D). At LDL-C locus ABCA1, the reported GWAS index SNP rs1883025 consistently showed the strongest association within each of the three ancestry groups that we examined, but the significance level of the association was similar to those of the nearby SNPs. Trans-ethnic meta-analysis refined the signal by revealing that rs1883025 ($P=4.3 \times 10^{-17}$ and rs2575876 ($P=1.8 \times 10^{-15}$) displayed much stronger association than the neighboring SNPs ($P>8.4 \times 10^{-16}$) (Figure S5A–S5D).

Reported functional variants were frequently the most strongly associated ones at a signal

Among loci associated with at least one lipid trait ($P<10^{-4}$), at least 27 variants at 15 loci have been previously reported [18,22,23,25,26,28–47] to functionally influence gene expression or protein function in vitro (Table 5). Among the 27 variants, 17 are present on the MetaChip and two are well-represented by perfect proxies in complete LD ($r^2=1$) based on the 1000 Genomes Project EUR data. Of the 19 reported functional variants, 14 (74%) exhibited the strongest association $P$-value among all SNPs at that signal in at least one population. In addition, two more reported functional variants (APOB-rs7575840, $P=7.0 \times 10^{-17}$ and LPL-rs328, $P=2.3 \times 10^{-11}$) were in high LD ($r^2>0.95$) with the most strongly associated variants and showed similar evidence of association (APOB-rs934198, $P=3.7 \times 10^{-12}$, LPL-rs1803924, $P=1.1 \times 10^{-11}$). If we include these two variants, then 16 of the 19 (84%) reported functional variants displayed the strongest association $P$-value at the primary, secondary, or successive signals. The remaining three reported functional variants: LDLR-rs688 (N911N), LPL-rs1801177 (D9N), and HMGCR-rs3761740 (911C>A), were poorly tagged (LD $r^2<0.2$) by the strongest variants in our data. Additional functional variants may exist at these loci that have not yet been reported to change gene expression/protein function or that were not identified in our literature search. For example, P2739L and P14S that represented the two signals at APOB (Table 1) were predicted by PolyPhen [48] to be ‘probably damaging’ with a score of ‘1’, although their functional roles were unclear.
| SNP          | Annotation          | Effect/non-effect allele | European (n = 10,829) | Variance explained by the strongest signal | Variance explained by all signals | African American (n = 6,832) | East Asian (n = 9,449) |
|--------------|---------------------|--------------------------|-----------------------|------------------------------------------|---------------------------------|-----------------------------|------------------------|
|              |                     |                          | EAF                   | LD ($r^2$/D) * d |         |                       | EAF                   | p b | p         | EAF                   | p b | p         |
| APOA5 for TG |                     |                          | 0.778                 | 0.108           | 9.7E-44  | 1.8% 2.4% 0.673 - 0.034 9.8E-05 0.643 - 0.073 1.2E-20 |
| rs3741298    | ZNF259-intron T/C   |                          | 0.041                 | 0.033           | 0.018   | 0.128 7.8E-14 0.012 0.030 0.045 0.042 - 0.023 0.24 |
| rs75919952   | --- T/C             |                          | 0.091                 | 0.400           | 0.151   | 9.3E-05 0.058 0.943 - 0.040 0.023 0.771 - 0.093 1.2E-25 |
| rs2075290    | ZNF259-intron T/C   |                          | 0.026                 | 0.021           | 0.126   | 1.9E-18 0.092 1.5E-10 0.019 0.030 0.26 0.106 0.125 2.7E-08 |
| rs56131196   | APOC1-3'UTR A/G     |                          | 0.177                 | 0.058           | 0.098   | 6.7E-50 0.073 2.2E-26 0.332 - 0.017 0.026 0.137 - 0.058 6.9E-16 |
| rs35136575   | --- C/G             |                          | 0.739                 | 0.011           | 0.056   | 9.6E-05 0.075 2.6E-07 0.817 0.014 0.55 0.904 - 0.003 0.91 |
| CETP for HDL-C |                     |                          | 0.056                 | 0.050           | 5.4E-76 3.4% 4.0% 0.110 - 0.536 6.7E-75 0.086 - 0.411 1.1E-64 |
| rs35166922   | --- T/C             |                          | 0.716                 | 0.090           | 4.7E-59 2.3% 3.6% 0.854 - 0.071 2.0E-12 0.830 - 0.071 1.1E-26 |
| rs12720922   | CETP-intron A/G     |                          | 0.177                 | 0.058           | 0.098   | 6.7E-50 0.073 2.2E-26 0.332 - 0.017 0.026 0.137 - 0.058 6.9E-16 |
| rs5883      | CETP-F287F T/C      |                          | 0.046                 | 0.035           | 0.055   | 5.0E-06 0.065 6.2E-08 0.101 0.088 1.3E-13 0.010 0.017 0.70 |
| PCSK9 for LDL-C |                     |                          | 0.040                 | 0.384           | 2.8E-30 1.2% 1.3% 0.003 - 0.595 2.3E-03 - - - - |
| rs11591147   | PCSK9-R46L T/G      |                          | 0.571                 | 0.000           | 0.086   | 1.3E-11 0.057 9.4E-06 0.292 0.055 7.4E-03 - 0.761 0.048 2.6E-03 |
| GCGR for TG  |                     |                          | 0.350                 | 0.069           | 4.4E-24 0.9% 1.0% 0.149 0.065 2.2E-08 0.484 0.056 1.5E-13 |
| rs1260326    | GCGR-P446L T/C      |                          | 0.949                 | 0.042           | 0.083   | 2.7E-08 0.060 7.6E-05 0.483 0.023 5.4E-03 0.999 0.191 0.21 |
| rs13399758   | CAD-intron A/G      |                          | 0.751                 | 0.022           | 0.116   | 3.7E-17 0.047 3.0E-15 0.481 - 0.034 2.2E-06 0.598 - 0.037 1.8E-13 |
| LIPC for HDL-C |                     |                          | 0.327                 | 0.051           | 2.5E-21 0.8% 1.4% 0.160 0.020 0.045 0.183 0.031 1.3E-06 |
| rs10468017   | --- T/C             |                          | 0.751                 | 0.022           | 0.116   | 3.7E-17 0.047 3.0E-15 0.481 - 0.034 2.2E-06 0.598 - 0.037 1.8E-13 |
| rs1077834    | UPCS-5'UTR T/C      |                          | 0.810                 | 0.131           | 0.092   | 2.5E-10 0.068 5.1E-05 0.446 0.123 1.2E-07 0.966 - 0.001 0.99 |
| APOB for LDL-C |                     |                          | 0.298                 | 0.116           | 3.7E-17 0.7% 0.8% 0.138 0.057 0.037 0.138 0.058 3.3E-03 |
| rs934198     | --- T/G             |                          | 0.810                 | 0.131           | 0.102   | 2.5E-10 0.068 5.1E-05 0.446 0.123 1.2E-07 0.966 - 0.001 0.99 |
| rs668948     | --- A/G             |                          | 0.014                 | 0.014           | 0.098   | -0.044 1.5E-05 0.860 - 0.018 0.12 0.905 0.008 0.55 |
| LPL for TG   | 3'UTR T/C           |                          | 0.258                 | 0.033           | 1.4E-09 0.3% 0.4% 0.505 0.047 3.5E-11 0.182 0.022 6.8E-04 |
| rs15285      | 3'UTR A/G           |                          | 0.360                 | 0.241           | 0.031   | 4.3E-09 -0.023 7.3E-05 0.167 - 0.014 0.13 0.837 - 0.018 3.7E-04 |

*LD ($r^2$/D) with SNP showing the strongest evidence of association at each locus.

1*P* effect size from an additive model and corresponding to the effect allele, in the unit of mmol/L for HDL-C, LDL-C and natural log transformed TG.

2*P* values of sequential conditional analyses, in which we added the SNP with the strongest evidence of association into the regression model as a covariate and tested for the next strongest SNP until the strongest SNP showed a conditional *P* value $> 10^{-4}$ and had no annotation suggesting potential function.

3*P* values of initial association in African Americans and East Asians.

4Variance explained by SNPs at each locus was estimated based on European samples.
Table 3. Lipid loci with multiple signals in East Asians.

| SNP                                      | Annotation     | Effect/non- | East Asian (n = 9,449) | Variance explained by the strongest signal | Variance explained by all signals | African American (n = 6,832) | European (n = 10,829) |
|------------------------------------------|----------------|-------------|------------------------|-------------------------------------------|---------------------------------|------------------------------|----------------------|
|                                          |                | Effect/allele |                        |                                            |                                 |                              |                      |
|                                          |                | EAF          | LD (r^2/D)*β^b          | P_initial β^b                              | P_conditional ^c                |                              |                      |
| APOA5 for TG                             | APOA5: -3A>G   | T/C          | 0.725                  | -----                                     | 2.6%                            | 3.4%                         | 0.851                |
|                                          |                | α             | 0.0158                 | 7.2E-68                                   | 1.4E-03                         | 8.9E-05                      | 8.5E-36              |
|                                          |                | α             | 0.0021                 | 0.204                                     | 0.028                           | 0.0038                       | 0.269                |
|                                          |                | θ             | 0.0001                 | 0.028                                     | 0.012                           | 0.0005                       | 0.0001               |
| TOMM40-APOE-APOC4 for LDL-C              |                 | T/C          | 0.086                  | -----                                     | ------                          | 8.0%                         | 9.0%                 |
|                                          |                | α             | 0.0158                 | 7.2E-68                                   | 1.4E-03                         | 8.9E-05                      | 8.5E-36              |
|                                          |                | α             | 0.0021                 | 0.204                                     | 0.028                           | 0.0038                       | 0.269                |
|                                          |                | θ             | 0.0001                 | 0.028                                     | 0.012                           | 0.0005                       | 0.0001               |
| CETP for HDL-C                           |                 | T/C          | 0.168                  | -----                                     | 1.0%                            | 2.3%                         | 0.146                |
|                                          |                | α             | 0.0158                 | 7.2E-68                                   | 1.4E-03                         | 8.9E-05                      | 8.5E-36              |
|                                          |                | α             | 0.0021                 | 0.204                                     | 0.028                           | 0.0038                       | 0.269                |
|                                          |                | θ             | 0.0001                 | 0.028                                     | 0.012                           | 0.0005                       | 0.0001               |
| ABO for LDL-C                            |                 | A/G          | 0.086                  | 0.00/1.00                                | 0.173                           | 3.8E-06                       | 0.024                |
|                                          |                | α             | 0.0158                 | 7.2E-68                                   | 1.4E-03                         | 8.9E-05                      | 8.5E-36              |
|                                          |                | α             | 0.0021                 | 0.204                                     | 0.028                           | 0.0038                       | 0.269                |
|                                          |                | θ             | 0.0001                 | 0.028                                     | 0.012                           | 0.0005                       | 0.0001               |
| ADAMTS-11                                 |                 | A/G          | 0.162                  | -----                                     | 1.1E-08                         | 0.8%                         | 0.121                |
|                                          |                | α             | 0.0158                 | 7.2E-68                                   | 1.4E-03                         | 8.9E-05                      | 8.5E-36              |
|                                          |                | α             | 0.0021                 | 0.204                                     | 0.028                           | 0.0038                       | 0.269                |
|                                          |                | θ             | 0.0001                 | 0.028                                     | 0.012                           | 0.0005                       | 0.0001               |

*LD (r^2/D) with SNP showing the strongest evidence of association at each locus.

**Effect size from an additive model and corresponding to the effect allele, in the unit of mmol/L for HDL-C, LDL-C and natural log transformed TG.

^P values of sequential conditional analyses, in which we added the SNP with the strongest evidence of association into the regression model as a covariate and tested for the next strongest SNP until the strongest SNP showed a conditional P value > 10^-4 and had no annotation suggesting potential function.

^Variance explained by SNPs at each locus was estimated based on CLHNS samples (n = 1,716).

^P values of initial association in African Americans and Europeans.

doi:10.1371/journal.pgen.1003379.t003
These functional variants covered a wide allele frequency spectrum (MAF: 0.003–0.481), including five less common or rare variants observed only in African Americans.

**Discussion**

This study evaluated densely spaced SNPs at 58 lipid loci across three ancestrally diverse populations. The results support evidence that allelic heterogeneity is a frequent feature of polygenic traits [5,49] and extend the findings to non-European populations, especially to African ancestry populations that have high levels of haplotype diversity. The results also provide strong evidence that fine mapping at GWAS loci can identify population-specific signals. Despite comparable sample sizes, we identified more signals per locus and more signals overall in African Americans (34 signals at 10 loci) compared to Europeans (21 signals at nine loci) and East Asians (nine signals at four loci), and 15 of the 34 signals identified in African Americans were population-specific (Table 1, Table 2, Table 3). These observations may reflect the larger number of SNPs genotyped in African Americans (Table S2), variation across populations subject to natural selection during human evolution [14], or genetic drift [50]. Due to the varied number of signals per locus, different associated markers, and different effect sizes, the phenotypic variance explained differs across populations [51–53]. Sampling variability, epistasis, and gene-environment interactions may cause over- or under-estimation of the proportion of explained phenotypic variance. In this study, we also observed that many population-specific signals, including those at PCSK9 and APOA5, are largely confirmatory [20,22,54]; however, the association evidence at other signals, in particular the additional signals at APOE, LDLR, and APOC1 identified by the conditional analyses, requires replication in future studies.

At PCSK9, the strongest signal C679X identified in African Americans is population-specific and showed substantially stronger evidence of association with LDL-C ($P = 4.1 \times 10^{-22}$) compared to the GWAS index SNP rs2479409 [5] ($P = 0.12$) and the most strongly associated SNP R46L identified via fine-mapping [7] ($P = 2.3 \times 10^{-5}$), both of which were previously reported in Europeans. The proportion of phenotypic variance explained in African Americans increased from 0.16% by the GWAS index SNP to 1.3% by the Metabochip signal C679X, and all variants at the locus together explained 3.6% of the total variation in LDL-C, providing evidence that heritability at identified loci may be underestimated by GWAS [7]. A limitation of these variance estimates is that calculations included the SNPs based simply on their significant association $P$-values rather than the variants with biological function, which could over-estimate effects due to the winner’s curse.

Results across the genotyped loci demonstrated that the majority of signals were represented by common variants, yet high-density genotyping also identified less common and rare variants associated with lipid traits. At PCSK9, the MAFs of six out of the seven signals were <0.05 in African Americans. These signals, along with other low frequency variants identified at APOE, LDLR, LCAT, APOB, APOC1, and LPL provide evidence of the substantial contribution of low frequency genetic variants to the variance of lipid traits [6]. Other variants, some with very low allele frequency, may exist at these loci, suggesting that future sequencing studies may identify additional functional variants that influence lipid variation.

Sequential conditional analyses provided further insight into the genetic architecture of the established lipid loci by explaining additional phenotypic variation and revealing complex patterns of
Table 4. Trans-ethnic fine-mapping narrowed the association signals.

| Locus/Trait | SNP | Meta-analysis | East Asian | African American | European |
|-------------|-----|---------------|------------|-----------------|----------|
|             |     | P meta | β | MAF | P | β | MAF | P | β | MAF | P |
| GCKR | P446L | 1.6E-42 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 | 0.72 |
| PPP1R3B | rs6601299 | 8.8E-10 | + | 0.06 | 8.8E-08 | + | 0.05 | 8.8E-08 | + | 0.05 | 8.8E-08 | + | 0.05 |
| LCAT | SLC12A4 | 9.0E-12 | + | 0.04 | 9.0E-07 | + | 0.04 | 9.0E-07 | + | 0.04 | 9.0E-07 | + | 0.04 |
| ABCA1 | rs1883025 | 4.3E-17 | + | 0.02 | 4.3E-11 | + | 0.02 | 4.3E-11 | + | 0.02 | 4.3E-11 | + | 0.02 |

a met: P meta; b Direction: effect direction of each individual studies in the order of ARIC, MEC, WHI batch1, WHI batch2, HyperGEN, CLHNS, TAICHI, Finnish T2D, Finnish unaffected, Norwegian T2D and Norwegian unaffected.

d I: Index of the degree of heterogeneity.

Trans-Ethnic Fine-Mapping of Lipid Loci

association. We observed loci at which signals were not independent of each other, but partially correlated based on moderate LD estimates and changes of association statistics before and after accounting for other signals. For these dependent signals, such as those at TOMM4-APOE-APOC4, the significance of residual association would increase when trait-increasing alleles were present on opposite haplotypes and decrease when trait-increasing alleles were on the same haplotype. Other signals that appeared to be independent on the basis of low pairwise LD and unchanged association evidence after conditional analysis may still be partially tagging an un-typed, yet influential, variant [55–57]. Therefore, deeper sequencing that identifies all variants at a locus will be required to characterize more fully the allelic heterogeneity and the patterns of association.

One of the major goals of high-density genotyping is to aid in identification of the functional variants by recognizing the most compelling candidate variants for experimental study. Because of the diverse LD structure across populations, particularly in terms of the limited LD extent in African ancestry populations, trans-ethnic fine-mapping of GWAS loci can narrow the region where functional variants are most likely to reside. This study was able to narrow the association signals at five lipid loci, based on the much smaller subsets of most strongly associated variants located in smaller regions. One signal was localized to a reported causal variant (GCKR-P446L) [28] and another to an uncharacterized nonsynonymous variant (SLC12A4-E4G near LCAT). These findings demonstrate that trans-ethnic association analyses can increase the resolution of fine-mapping by enlarging the haplotypic diversity of samples with different ancestries and consequently, narrowing the sets of candidate functional variants [58,59]. The previously described functional variants at LCAT [44] and ABCA1 [42,43], which are not present on the Metabochip, were physically located 22 kb and >43 kb away from the narrowed association signals observed in this study (Table 4).

Refining signals by trans-ethnic meta-analysis largely relies not only on the existence of distinct LD patterns across ancestry groups but also on shared functional variants. If functional variants are shared across populations, as observed with GCKR-P446L, performing trans-ethnic meta-analysis and integrating LD information across different populations may refine the signal. On the contrary, if trait variation is influenced by distinct functional variants across populations, as our data suggest for E4G (Figure S6A–S6D), the lead SNPs produced by meta-analysis would be influenced by the sample size, magnitude of genetic effects, and allele frequencies. Similarly, in the case of population-specific functional variants, such as those at PCSK9, the results from meta-analysis would reflect the association in one particular population rather than the combined effect across populations if signals unique to this population drive the results. Therefore, accurate assessment of allelic variability is needed on a population-by-population and locus-by-locus basis.

Although genotype imputation has become a standard practice to increase genome coverage in GWAS by predicting the genotypes at SNPs that are not directly genotyped, imputation accuracy tends to be lower for rare variants owing to the lower degree of LD and the more challenging haplotype reconstruction [60]. In addition, African American samples pose a challenge for imputation due to their varying degree of admixture [61]. A major strength of our study is that all variants we tested for association were directly genotyped using the Metabochip, which was designed to provide a high-density coverage for both overall SNPs and low frequency variants concentrated around GWAS-identified loci and/or signals [9,10]. This approach increases the reliability of our association results overall, but in particular the variants with low allele frequencies.

In conclusion, we performed a large-scale trans-ethnic fine-mapping study to investigate the established lipid loci using the Metabochip...
Table 5. Reported functional variants exhibited the strongest association at a signal ($P<10^{-5}$).

| Reported functional variants [ref] | Reported functional variants on Metabochip | Variants with strongest association at a signal | Signal | Ethnic group* MAF | Notes |
|-----------------------------------|------------------------------------------|---------------------------------------------|--------|------------------|-------|
| PCSK9: rs28362286 (C679X) [22]    | Yes                                      | rs28362286                                  | 1st    | AA 0.009         | Same variant |
| PCSK9: rs28362263 (A443T) [29]    | Yes                                      | rs28362263                                  | 2nd    | AA 0.097         | Same variant |
| PCSK9: rs28362261 (N425S) [30]    | Yes                                      | rs28362261                                  | 3rd    | AA 0.017         | Same variant |
| PCSK9: rs67608943 (Y142X) [22]    | Yes                                      | rs67608943                                  | 4th    | AA 0.004         | Same variant |
| PCSK9: rs72646508 (L253F) [22]    | Yes                                      | rs72646508                                  | 5th    | AA 0.003         | Same variant |
| APOE: rs7412 (R176C) [23]         | Yes                                      | rs7412                                      | 1st    | AA, ASN, EUR 0.056–0.110 | Same variant |
| APOE: rs769455 (R163C) [31]       | Yes                                      | rs769455                                    | 2nd    | AA 0.020         | Same variant |
| APOA5: rs3135506 (S19W) [26]      | Yes                                      | rs3135506                                   | 1st    | AA 0.058         | Same variant |
| APOA5: rs651821(-3A>G) [32]       | Yes                                      | rs651821                                    | 1st    | ASN 0.275        | Same variant |
| APOA5: rs2075291 (G148C) [25]     | Yes                                      | rs2075291                                   | 2nd    | ASN 0.064        | Same variant |
| GCKR: rs126032 (L446P) [28]       | Yes                                      | rs126032                                    | 1st    | AA, EUR 0.149–0.350 | Same variant |
| SORT1: rs12740374 [18]           | Yes                                      | rs12740374                                  | 1st    | AA 0.247         | Same variant |
| CETP: rs17231520 [33]             | Yes                                      | rs17231520                                  | 3rd    | AA 0.069         | Same variant |
| LIPC: rs2070895 [34]              | Proxy: rs1077834 (LD $r^2 = 1.00$)       | rs1077834                                   | 1st, 2nd | AA, EUR 0.481 | LD $r^2 = 1.00$ |
| APOB: rs7575840 [35]              | Yes                                      | rs934198                                    | 1st    | EUR 0.298        | $LD r^2 = 0.98$ |
| LPL: rs328 (S447X) [36]           | Yes                                      | rs1803924                                   | 1st    | ASN 0.095        | $LD r^2 = 0.96$ |
| LDLR: rs688 (N591K) [37]          | Yes                                      | rs73015011, rs112898275                      | 1st    | AA, EUR ----     | $LD r^2<0.01$ |
| LPL: rs1801177 (DN9) [38]         | Yes                                      | rs75551077, rs15285                         | 1st    | AA, EUR ----     | $LD r^2<0.02$ |
| HMGCR: rs3761740 (-911C>A) [39]   | Proxy: rs17238330 (LD $r^2 = 1.00$)      | rs12916                                     | 1st    | EUR ----         | $LD r^2<0.20$ |
| LDLR: -139C>G [40]               | No                                       | ----                                        | ----   | ----             | ---- |
| LPL: rs268 (N291S) [41]           | No                                       | ----                                        | ----   | ----             | ---- |
| ABOA1: rs9282541 (R2130C) [42]    | No                                       | ----                                        | ----   | ----             | ---- |
| ABOA1: rs2066715 (V825I) [43]     | No                                       | ----                                        | ----   | ----             | ---- |
| LCAT: rs28940888(-159199) [44]    | No                                       | ----                                        | ----   | ----             | ---- |
| PLTP: R235W [45]                 | No                                       | ----                                        | ----   | ----             | ---- |
| LIPC: rs277963034 (A396S) [46]    | No                                       | ----                                        | ----   | ----             | ---- |
| LIPC: rs34474737 [47]             | No                                       | ----                                        | ----   | ----             | ---- |

*AA, African American; EUR, European; ASN, East Asian.
doi:10.1371/journal.pgen.1003379.t005

Trans-Ethnic Fine-Mapping of Lipid Loci

high-density genotyping array and focusing on diverse groups including African Americans, East Asians, and Europeans. Our results highlight the value of high-density genotyping in diverse populations to identify a wider spectrum of susceptibility variants at established loci, both in terms of additional signals and in terms of population-specific and/or potentially functional variants. The additional signals revealed through the sequential conditional analyses lead to a 1.3- to 1.8-fold increase in the explained phenotypic variance across the different populations. In addition, integrating diverse LD patterns across diverse ancestry groups allows for the refinement of association signals. Lastly, our findings that 74% of the reported functional variants exhibited the strongest association at these densely typed signals suggest that at loci and signals where functional variants are unknown, the variants with strongest association may be good candidates for functional assessment.

Materials and Methods

Study populations and phenotypes

The 6,832 African Americans studied are comprised of individuals from the Atherosclerosis Risk in Communities Study (ARIC) [62], the Multicentric Cohort Study (MEC) [63], and the Women’s Health Initiative [WHI] [64,65] that are part of Population Architecture using Genomics and Epidemiology (PAGE) consortium [66] and from Hypertensive Genetic Epidemiology Network (HyperGEN) [67]. The 9,449 East Asian samples are comprised of 1,716 Filipinos from the Cebu Longitudinal Health and Nutrition Survey (CLHNS) [67] and 7,733 Chinese from Taiwan-Metabochip Study for Cardiovascular Disease (TAICHI). The 10,829 European samples are comprised of Finnish and Norwegian individuals; the Finns are from the Finland-United States Investigation of NIDDM Genetics (FUSION), Dehko 2D 2007 (D2D2007), Diabetes Prevention Study (DPS), Dose-Responses to Exercise Training (DR’s EXTRA), and Metabolic Syndrome in Men (METSIM) [69,70], and the Norwegians were from the cohorts of Nord-Trøndelag Health Study (HUNT 2) and the Tromso Study (TROMSO) [71,72].

All study protocols were approved by Institutional Review Boards at their respective sites. Brief descriptions of the studies are provided in the Text S1. General characteristics and measurements of TG, HDL-C, and LDL-C in each cohort are summarized in Table S1. Values of triglycerides were natural log transformed to approximate normality in each study sample separately.
Genotyping
We genotyped all study samples with the Metabochip according to the manufacturer’s protocol (Illumina, San Diego, CA, USA). Table S1 summarizes the quality control criteria of genotyping, including call rate, sample success rate, Hardy-Weinberg equilibrium, and MAF that varied across studies.

Statistical analyses
We applied multiple linear regression models and assumed an additive mode of inheritance to test for association between genotypes and HDL-C, LDL-C, or log-transformed triglycerides. We performed each test of association separately in each of the 11 groups (Table S1) prior to meta-analysis. We constructed principal components (PCs) using the software EIGENSOFT. We used age and sex as covariates in each individual cohort; other cohort-specific covariates including age², enrollment site, socioeconomic status, and principal components varied across studies (Table S1). The European samples include type 2 diabetes (T2D) cases and unaffected controls; to avoid confounding due to T2D status, samples were analyzed separately as Finnish T2D patients, Finnish unaffected individuals, Norwegian T2D patients, and Norwegian unaffected individuals.

We first conducted the meta-analysis within the African Americans, East Asians, and Europeans separately. We then performed combined trans-ethnic meta-analyses by combining the statistics of each of the 11 participating groups to assess the association with the SNPs at the 58 lipids loci.

At loci that exhibited evidence of association at \( P < 10^{-4} \), we next performed a series of sequential conditional analyses by adding the most strongly associated SNP into the regression model as a covariate and testing all remaining regional SNPs for association. We conducted a set of sequential conditional analyses until the strongest SNP showed a value \( P < 10^{-4} \) and had no annotation or literature evidence that suggested a functional role.

For single SNP analyses, we applied PLINK (http://pngu.mgh.harvard.edu/~purcell/plink/) [73] for population-based studies. We used the R package GWAF [74] for the family-based study of HyperGEN. We applied an inverse variance-weighted fixed-effect meta-analysis implemented in METAL [75].

Unless otherwise noted, linkage disequilibrium estimates were obtained from the 1000 Genomes Project November 2010 release. SNP positions correspond to hg18.

We performed haplotype analysis at LDL-C locus \( TOMM40\)-APOE-APOC4 in 5,593 unrelated African Americans from the PAGE consortium, using the ‘haplo.stat’ R package. Haplotypes and haplotype frequencies were estimated using the R function ‘haplo.em’.

The association between haplotypes and LDL-C was assessed using the R function ‘haplo.glm’. An additive model was assumed, in which the regression coefficient \( \beta \) represents the expected change in LDL-C level with each additional copy of the specific haplotype compared with the reference haplotype, which was set as the A-A (trait increasing-increasing) haplotype.

We created the regional association plots using LocusZoom [76]. To plot the association results in Europeans and East Asians, we used the LocusZoom-implemented LD estimates from the 1000 Genomes Project (June 2010) CEU and CHB+JPT samples, whose LD structures are similar to our samples with European and East Asian ancestries. We applied the user-supplied LD calculated from the genotype data of the PAGE African American samples to plot the regional association in African Americans [9], because the LD patterns may vary from any pre-computed LD sources implemented in LocusZoom.

We evaluated the proportion of variance explained by a single SNP or any given locus by including the SNP or a set of SNPs into a linear regression model with all covariates used in association analysis and calculating the \( R^2 \) for the full model. We subtracted the variance explained by a basic model in which only covariates were included from the variance we obtained from the full model. We performed these analyses using SAS version 9.2 (SAS Institute, Cary, NC, USA).

Supporting Information
Figure S1 LDL-C locus \( TOMM40\)-APOE-APOC4 exhibited seven signals in African Americans. Each SNP was colored according to its LD \( r^2 \) in PAGE consortium with the strongest SNP rs7412 (R176C) colored in purple. (PDF)

Figure S2 Association at TG locus GCKR in Europeans (A), East Asians (B), African Americans (C), and trans-ethnic meta-analysis (D). Index SNP rs1260526 (P446L) is the variant showing the strongest evidence of association in trans-ethnic meta-analysis. (PDF)

Figure S3 Association at LDL-C locus ABO in Europeans (A), East Asians (B), African Americans (C), and trans-ethnic meta-analysis (D). Index SNP rs2519093 is the variant showing the strongest evidence of association in trans-ethnic meta-analysis. (PDF)

Figure S4 Association at HDL-C locus LCAT in Europeans (A), East Asians (B), African Americans (C), and trans-ethnic meta-analysis (D). Index SNP rs3785100 (S1C12A-E4G) is the variant showing the strongest evidence of association in trans-ethnic meta-analysis. (PDF)

Figure S5 Association at HDL-C locus ABCA1 in Europeans (A), East Asians (B), African Americans (C), and trans-ethnic meta-analysis (D). Index SNP rs1883025 is the variant showing the strongest evidence of association in trans-ethnic meta-analysis. (PDF)

Figure S6 Association at TG locus APOA5 in Europeans (A), East Asians (B), African Americans (C), and trans-ethnic meta-analysis (D). The SNPs rs3741298, rs651821 (-3A>G), rs3135506 (S19W), and rs662799 that exhibited the smallest \( P \) values in Europeans, East Asians, African Americans, and the trans-ethnic meta-analysis are indicated. (PDF)

Table S1 Characteristics of the study samples. (PDF)

Table S2 Number of SNPs at each locus for analysis in each of the three ancestry groups. (PDF)

Table S3 Lead SNP at TG (A), HDL-C (B), and LDL-C (C) loci within each ancestry group and their relative significance compared to reported GWAS index SNPs. (PDF)

Table S4 SNPs with the strongest association at TG (A), HDL-C (B) and LDL-C (C) loci in combined trans-ethnic meta-analysis and their associations within ancestry groups. (PDF)

Table S5 LDL-C association with haplotypes consisting of the third (rs1038026) and the fourth (rs157588) signals at \( TOMM40\)-APOE-APOC4 cluster. (PDF)
Text S1  Study description.

References

1. Kathiresan S, Melander O, Guiducci C, Surh A, Burt NP, et al. (2008) Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet 40: 189–197.

2. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, et al. (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40: 161–169.

3. Solberg LA, Shuldiner AR, Willer CJ, Sanna S, Rifai N, et al. (2009) Loci associated with blood lipids and risk of coronary heart disease. Nat Genet 41: 47–55.

4. Kathiresan S, Willer CJ, Peloos GM, Demissie S, Musunuru K, et al. (2009) Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 41: 56–65.

5. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, St filliou DM, et al. (2010) Biological, clinical and population relevance of 95 loci for blood lipid traits. Nature 464: 757–761.

6. McCarthy MI, Abecasis GR, Cardon LR, Goldstein DB, Little J, et al. (2008) Genome-wide association studies for complex traits: consensus, uncertainty and challenges. Nat Rev Genet 9: 356–369.

7. Sanna S, Li B, Mulas A, Sidore C, Kang HM, et al. (2011) Fine mapping of five loci associated with low-density lipoprotein cholesterol detects variants that double the explained heritability. PLoS Genet 7: e1002198. doi:10.1371/journal.pgen.1002198

8. Hartimannis T, Jones MR, McGovern DP, Shig DH, Barrett RJ, et al. (2011) Variants in ZNF365 isoform D are associated with Crohn’s disease. Gut 60: 1268–1276.

9. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, et al. (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40: 161–169.

10. Solberg LA, Shuldiner AR, Willer CJ, Sanna S, Rifai N, et al. (2009) Loci associated with blood lipids and risk of coronary heart disease. Nat Genet 41: 47–55.

11. Kathiresan S, Willer CJ, Peloos GM, Demissie S, Musunuru K, et al. (2009) Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 41: 56–65.

12. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, St filliou DM, et al. (2010) Biological, clinical and population relevance of 95 loci for blood lipid traits. Nature 464: 757–761.

13. Sanna S, Li B, Mulas A, Sidore C, Kang HM, et al. (2011) Fine mapping of five loci associated with low-density lipoprotein cholesterol detects variants that double the explained heritability. PLoS Genet 7: e1002198. doi:10.1371/journal.pgen.1002198

14. Hartimannis T, Jones MR, McGovern DP, Shig DH, Barrett RJ, et al. (2011) Variants in ZNF365 isoform D are associated with Crohn’s disease. Gut 60: 1268–1276.

15. Willer CJ, Sanna S, Jackson AU, Scuteri A, Bonnycastle LL, et al. (2008) Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 40: 161–169.

16. Solberg LA, Shuldiner AR, Willer CJ, Sanna S, Rifai N, et al. (2009) Loci associated with blood lipids and risk of coronary heart disease. Nat Genet 41: 47–55.

17. Kathiresan S, Willer CJ, Peloos GM, Demissie S, Musunuru K, et al. (2009) Common variants at 30 loci contribute to polygenic dyslipidemia. Nat Genet 41: 56–65.

18. Musunuru K, Strong A, Frank-Kamenetsky M, Lee NE, Ahfeldt T, et al. (2010) From noncoding variant to phenotype via SORT1 at the 1p13 cholesterol locus. Nat Genet 42: 746–749.

19. Teo YY, Small KS, Kwiatkowski DP (2010) Methodological challenges of genome-wide association studies in Africa. Nat Rev Genet 11: 149–160.

20. Colhoun JM, Pershing L, Kotowski IK, Gorman R, Garcia CK, et al. (2005) Low LDL cholesterol in individuals of African descent resulting from frequent non-synonymous mutations in PCSK9. Nat Genet 37: 161–165.

21. Kotowski IK, Pershing L, Duke A, Cooper RS, Vegal G, et al. (2006) A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am J Hum Genet 78: 410–422.

22. Zhao Z, Tsaih-Wosornu V, Laiacce TG, Kinch L, Grishin NV, et al. (2006) Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 79: 514–523.

23. Rall SC, Jr., Weisgraber KH, Innerarity TL, Malley RW (1982) Structural basis for receptor binding heterogeneity of apolipoprotein E: from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci U S A 79: 4696–4700.

24. Ward H, Mirou NR, Bowman R, Luben R, Wareham NJ, et al. (2009) APOE genotype, lipids, and coronary heart disease risk: a prospective population study. Am J Hum Genet 85: 1424–1429.

25. Huang YJ, Lin YL, Chiang CI, Yen CT, Lin SW, et al. (2012) Functional importance of apolipoprotein A5 1585G in the activation of lipoprotein lipase. Clin Chim Acta 413: 246–250.

26. Talmud PJ, Palmen J, Punt W, Liu L, Humphries SE (2005) Determination of the functionality of common APOA5 polymorphisms. J Biol Chem 280: 28215–28220.

27. McCarthy MI (2008) Casting a wider net for diabetes susceptibility genes. Nat Genet 40: 1039–1040.

28. Rees MG, Winzorius S, Schulz J, Waterstradt R, Beer NL, et al. (2012) Cellular characterization of the GCKR P44L variant associated with type 2 diabetes risk. Diabetologia 55: 114–122.

29. Benjamini Y, Pinhasi D, Karlins E, Essah NA, Seldin MF (2006) The propoprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem 281: 30561–30572.

30. Faasoo T, Sun SX, Patel DD, Soutar AK (2009) Degradation of LDLR protein mediated by ‘gain of functions’ PCSK9 mutants in normal and ARH cell lines. Atherosclerosis 203: 166–171.

31. Sullivan PM, Mezdour H, Quarfordt SH, Maeda N (1998) Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. J Clin Invest 102: 130–135.

32. Palmen J, Smith AJ, Dorfmeister B, Punt W, Humphries SE, et al. (2012) Cellular characterization of the GCKR P44L variant associated with type 2 diabetes risk. Diabetologia 55: 114–122.

33. Benjamini Y, Pinhasi D, Karlins E, Essah NA, Seldin MF (2006) The propoprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem 281: 30561–30572.

34. Faasoo T, Sun SX, Patel DD, Soutar AK (2009) Degradation of LDLR protein mediated by ‘gain of functions’ PCSK9 mutants in normal and ARH cell lines. Atherosclerosis 203: 166–171.

35. Sullivan PM, Mezdour H, Karlins E, Essah NA, Seldin MF (2006) The propoprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J Biol Chem 281: 30561–30572.
55. Wood AR, Hernandez DG, Nalls MA, Yaghootkar H, Gibbs JR, et al. (2011) Enhanced signal detection with imputation-based mixed linear models in association analysis. Am J Hum Genet 89: 95–108.

56. Trynka G, Hunt KA, Bockett NA, Romanos J, Mistry V, et al. (2011) Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 43: 1193–1203.

57. Spencer CE, Hechter E, Vukcevic D, Donnelly P (2011) Quantifying the underestimation of relative risks from genome-wide association studies. PLoS Genet 7: e1001337. doi:10.1371/journal.pgen.1001337

58. Teo YY, Ong RT, Sinn X, Tai ES, Chia KS (2010) Identifying candidate causal variants via trans-population fine-mapping. Genet Epidemiol 34: 653–664.

59. Teo YY, Sim X (2010) Patterns of linkage disequilibrium in different populations: implications and opportunities for lipid-associated loci identified from genome-wide association studies. Curr Opin Lipidol 21: 104–115.

60. Liu EY, Buyse S, Aragaki AK, Peters U, Boerwinkle E, et al. (2012) Genotype Imputation of MetaboChipCPs Using a Study-Specific Reference Panel of ~4,000 Haplotypes in African Americans From the Women’s Health Initiative. Genet Epidemiol 36: 107–117.

61. Rosenberg NA, Huang L, jewett EM, Szpiech ZA, Jankovic I, et al. (2010) Genome-wide association studies in diverse populations. Nat Rev Genet 11: 356–366.

62. The ARIC investigators (1989) The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators. Ann J Epidemiol 129: 687–702.

63. Colonel LN, Althuuler D, Henderson BE. (2004) The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer 4: 519–529.

64. The Woman’s Health Initiative Study Group (1998) Design of the Women’s Health Initiative Clinical trial and observational study. The Women’s Health Initiative Study Group. Control Clin Trials 19: 61–109.

65. Anderson GL, Manson J, Wallace R, Land B, Hall D, et al. (2003) Implementation of the Women’s Health Initiative Study design. Ann Epidemiol 13: S3–17.

66. Maitre TC, Amhite JL, Buyuke S, Carolon CS, Cole SA, et al. (2011) The Next PAGE in understanding complex traits: design for the analysis of Population Architecture Using Genetics and Epidemiology (PAGE) Study. Ann J Epidemiol 174: 849–859.

67. Williams RR, Rao DG, Ellison RC, Arnett DK, Heiss G, et al. (2000) NHLBI family blood pressure program: methodology and recruitment in the HyperGEN network. Hypertension genetic epidemiology network. Ann Epidemiol 10: 390–400.

68. Adair LS, Popkin BM, Akin JS, Guilkey DK, Gullion S, et al. (2011) Cohort profile: the Cebu longitudinal health and nutrition survey. Int J Epidemiol 40: 618–625.

69. Scott JG, Mohlke KL, Bouxcatl LL, Willer CJ, Li Y, et al. (2007) A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 316: 1341–1345.

70. Stumvoll M, Linnenb M, Wilker JL, Haffner SM, D'Agostino RB, et al. (2001) Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. Diabetes 50: 1212–1221.

71. Middelbj RJ, Kruger O, Holmen J, Tverdal A, Claudi T, et al. (2011) Rapid changes in the prevalence of obesity and known diabetes in an adult Norwegian population. The Nord-Trondelag Health Surveys: 1984–1986 and 1995–1997. Diabetes Care 22: 1813–1820.

72. Joseph SW, Sarpberg BJ, Njuelad SJ, Schirm PH (2010) Incidence of and risk factors for type-2 diabetes in a general population: the Tromso Study. Scand J Public Health 38: 768–775.

73. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.

74. Chen YH, Yang Q (2010) GWAS: an R package for genome-wide association analyses with family data. Bioinformatics 26: 580–581.

75. Willer CJ, Li Y, Abecasis GR. (2010) METAL: fast and efficient meta-analysis of genome-wide association scans. Bioinformatics 26: 2190–2191.

76. Prüim RJ, Welch RP, Stanssens S, Tedeschi TM, Chines PS, et al. (2010) LocusZoom: Regional visualization of genome-wide association scan results. Bioinformatics 26: 2336–2337.